Merck Serono will develop and commercialize Ambrx' long-acting growth hormone products. The collaboration will focus initially on the development of ARX201, the most advanced product candidate, currently in Phase I/II trials. ARX201 has improved pharmacological properties, which should allow less frequent administration than the daily dosing regimen of currently available growth hormones, according to the companies.
Under the terms of the agreement, Merck Serono will receive worldwide commercialization rights for ARX201. Ambrx will receive initial payment and is eligible to undisclosed clinical, regulatory, and commercial milestone payments based on the successful development and commercialization of products as well as undisclosed royalties on net sales of such products.
Ambrx retains an option to co-promote products in the U.S. market. If the option is exercised, the companies will share U.S. commercialization expenses as well as profits.